Digital Angel Corp. (OTC: DIGA) said it has filed its Definitive 14C with the US Securities and Exchange Commission to satisfy the conditions of the share exchange agreement with VeriTeQ Acquisition Corp.
The Definitive 14C enables Digital Angel to effect a 1-for-30 reverse stock split, name change to VeriTeQ Corp. and stock symbol change.
The reverse stock split and name change were conditions to the share exchange agreement between VeriTeQ and Digital Angel, which was completed in July 2013. Digital Angel acquired all the outstanding shares of VeriTeQ from the VeriTeQ shareholders in exchange for 410,759 shares of Digital Angel´s Series C preferred stock. The share exchange resulted in a union of the two companies to focus on medical device identification and radiation dose measurement technologies for use in radiation therapy treatment.
The company has over 100 patents, patents pending, and exclusive licenses, and multiple regulatory approvals from the US Food and Drug Administration and CE marks, which enable the company to market its products in the European Union.
Digital Angel, through its VeriTeQ subsidiary, develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. For more information on VeriTeQ, visit www.veriteqcorp.com.